Refine by
Antigen Presentation Articles & Analysis: Older
37 news found
Protheragen focuses on delivering comprehensive vaccine development services, specifically designed to meet the distinct challenges presented by various pathogens. With advanced research equipment and an excellent expert team, the company can develop vaccines targeting different types of pathogens, including bacterial infections, fungal infections, viral infections, prion ...
The featured vaccine products supplied by Alfa Chemistry are listed as below: Nucleic Acid Delivery ExcipientsNucleotide vaccines, including mRNA vaccines with their intracellular antigen synthesis, have been shown to be potent activators of a cytotoxic immune response. However, the intracellular delivery of mRNA vaccines to the cytosol of antigen ...
The Product Manager of the Long-Read Sequencing Division announced the launch of the Human Leukocyte Antigen (HLA) Typing service to support high-resolution HLA typing in a rapid and cost-efficient manner. ...
“By locally ablating tumors with UNO we have shown that the recruitment of antigen-presenting cells (APCs) triggers T-cells to proliferate and mature, producing a long-term systemic immune response that reduces distant metastases and prolongs survival in ...
A case for antibody engineering B cells produce antibodies in response to the presence of antigens. These antibodies then recognize and bind to antigens, triggering one of several downstream activities, such as: Neutralization by alteration of the chemical composition of an antigen Immobilization of the ...
IRVINE, Calif. – AUG. 29, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced the publication of safety and efficacy results from Phase 1 and Phase 2 clinical trials investigating its anti-SARS-CoV-2 vaccine candidate AV-COVID-19 that is made at point-of-care by third-party personnel. The results were published in the article ...
IA-05 is a fully synthetic small molecule which that, in head-to-head preclinical studies against vaccines incorporating several existing adjuvants, including QS-21, demonstrated improved cross-presentation of antigens and well tolerability. Currently, QS-21-incorporated vaccines have shown better protection against virus infection. ...
(Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new data from a follow-up analysis of a subset of participants from the pivotal Phase 3 study (PROTECT) of the Company’s 3-antigen prophylactic hepatitis B (HBV) vaccine, were presented in an oral ...
Canadian biotechnology company ANGANY (www.ANGANY.com) is presenting its immunotherapy platform at BIO International Convention, a critical rendez-vous for the global pharmaceutical industry which takes place in San Diego, California between June 13th and 16th. ...
Ex vivo studies show that treatment with IO-108 produces pro-inflammatory activity and an enhanced antigen-presenting cell (APC) phenotype to multiple stimuli, including T cell activators, and STING and TLR agonists. ...
“Clinical data previously collected by Cancer Research UK demonstrated peripheral immunogenicity in patients with NSCLC treated with VAC2, providing support to the underlying mechanism of using allogeneic dendritic cells to present tumor-associated antigens to the body’s immune system. Simultaneous with Cancer Research UK efforts to complete ...
ABOUT LILRB4 (also known as ILT3) LILRB4, also known as ILT3, is an immune inhibitory transmembrane receptor expressed by monocytic myeloid cells, including dendritic cells, monocytes, monocytic myeloid-derived suppressor cells and tumor-associated macrophages. LILRB4 inhibits antigen-presenting cell function, resulting in immune tolerance. LILRB4 is also ...
The abstract title has been posted to the AACR Online Itinerary Planner, will be published in the online Proceedings of the AACR, and is detailed below. The data to be presented demonstrate significantly greater anti-tumor activity of cytoTIL15 therapy in vivo compared to conventional TIL + IL2 therapy in a human leukocyte antigen (HLA)-matched, allogeneic ...
This is achieved by delivering a DNA plasmid using Ichor’s TriGrid® 2.0 electroporation delivery device to enhance the uptake and presentation of cancer antigens to harness high avidity T cell responses. ...
ByScancell
The newly introduced antigens consist of five of the most common staphylococcus aureus enterotoxins and are ideal for in vitro detection and diagnostic studies. ...
The collaboration is centered around NexImmune’s artificial antigen presenting cells' (aAPCs) ability to expand neoantigen-specific CD8+ T cells in apheresis material provided by melanoma patients. ...
Details of selected oral and moderated poster presentations are listed below. NOTE: Axumin® (fluciclovine F 18) injection is FDA-approved for PET imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. Presentations noted by "*" discuss results of ...
VAXIMM’s plug and play DNA vaccination technology is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target a wide range of cancer-related antigens. The platform allows for fast and scalable manufacturing of personalized T-cell cancer vaccines and may overcome key challenges ...
In addition, two trials in progress posters are being presented, which showcases cohort B of the DEDUCTIVE HCC study that is currently enrolling HCC patients following prior bevacizumab and atezolizumab; and the Company, in collaboration with the University of Florida Health Cancer Center, is presenting the study design for the Phase 1b/2 IMMCO-1 trial of ...
Based on the results of these studies and on further promising results presented in scientific literature, the company has decided to accelerate the development within the immuno-oncology field in two priority focus areas – therapeutic vaccines and vectors for “drug delivery”. As a first priority, Abera will conduct studies within the concept of therapeutic ...